Susumu Tonegawa, PhD, at MIT

Experimental Compound FRAX486 Reverses Signs of Fragile X in Mice

With $81K from FRAXA, Dr. Susumu Tonegawa at MIT studied the PAK enzyme as a potential Fragile X treatment target. Results published.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (40)